Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04363684 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04363684 · ClinicalTrials.gov record · last posted 2026-07-30

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

StatusRecruiting
PhaseNot specified
Started2020-03-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Protocol amendment history 3 changes detected by DataLookout

2026-07-31
Primary endpoint(s) modified
WasChange in Brain Volumes, Change in Multidomain Impairment Rating (MIR) Scale, Change in NIH Examiner Executive Composite Score
NowChange in Brain Volumes, Change in Multidomain Impairment Rating (MIR) Scale, Change in neuropsychological battery
2026-07-31
Primary completion pushed: 2026-06-30 → 2030-08-31
2026-07-31
Completion pushed: 2026-06-30 → 2030-08-31
Trial Details
NCT Number NCT04363684
Lead Sponsor Mayo Clinic
Collaborators: University of California, San Francisco, National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis +6 more
Enrollment 2,100 participants
Start Date 2020-03-01
Primary Completion 2030-08-31 (estimated)
Study Completion 2030-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30